Breast cancer is the most common type of cancer in women in the Netherlands. Increasingly, systemic chemotherapy is given prior to surgery. This strategy, known as neoadjuvant chemotherapy, aims to eliminate metastases and reduce tumours, facilitating breast conserving surgery. MRI is increasingly used to evaluate response to chemotherapy in breast cancer patients. Claudette Loo investigates the role played by MRI in monitoring the response to neodjuvant chemotherapy, with the ultimate aim of improving personalised cancer treatment.
C.E. Loo: Dynamic Contrast-Enhanced MRI for Monitoring Response to Neoadjuvant Chemotherapy in Breast Cancer.
Prof. R.G.H. Beets-Tan
Prof. S. Rodenhuis
Dr K.G.A. Gilhuijs
This event is open to the public.